Edition:
United States

VIVUS Inc (VVUS.O)

VVUS.O on Nasdaq

1.09USD
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
$1.09
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
589,352
52-wk High
$1.85
52-wk Low
$0.93

Latest Key Developments (Source: Significant Developments)

Vivus qtrly earnings per share $0.54
Wednesday, 8 Mar 2017 04:10pm EST 

Vivus Inc : Vivus reports fourth quarter and full year 2016 financial results . Vivus Inc - qtrly earnings per share $0.54 . Vivus Inc - total revenue, net for quarter was $81.8 million compared to $15.3 million . Vivus - about 100,000 qsymia prescriptions were dispensed in quarter , compared to 132,000 in same period in 2015 .Vivus Inc says in Q4 of 2016, recognized a one-time up-front license fee of $69.4 million.  Full Article

Vivus entered into settlement agreement with Hetero on Jan. 3
Monday, 9 Jan 2017 04:16pm EST 

Vivus Inc : On Jan 3, co entered into a settlement agreement with hetero - sec filing . Vivus- Settlement resolves co's lawsuit in response to Hetero's filing of ANDA, seeking to market generic versions of Stendra before expiration of asserted patents . Vivus - under settlement agreement, hetero was granted license to manufacture, commercialize generic version of stendra described in its ANDA filing in U.S. .Vivus - settlement agreement provides for full settlement of all claims asserted in suit, subject to court's acceptance of stipulation of dismissal.  Full Article

Vivus and Selten Pharma announce agreement for development and commercialization rights to treatments for PAH
Monday, 9 Jan 2017 09:00am EST 

Vivus Inc : Vivus and Selten Pharma announce agreement for the development and commercialization rights to treatments for Pulmonary Arterial Hypertension (PAH) . Vivus assumes all development and commercialization responsibilities . Vivus is responsible for all future financial obligations to Stanford under Stanford license .Selten will receive an upfront payment, development and sales milestone payments, tiered royalties on future sales of compounds.  Full Article

Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra
Monday, 3 Oct 2016 08:30am EDT 

VIVUS Inc : VIVUS Inc says additionally, Metuchen will be responsible for royalties due to Mitsubishi Tanabe Pharma corporation based on net sales . VIVUS and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra .VIVUS-Signed commercial supply agreement pursuant to which Co to be responsible for manufacture, supply of Stendra to Metuchen; VIVUS received $70 million.  Full Article

Vivus says extends return date of Stendra commercial rights
Monday, 29 Aug 2016 04:30pm EDT 

Vivus Inc [VVUS.O] : Vivus inc says extends return date of stendra commercial rights . Extension of termination date of license agreement between auxilium and vivus for stendra u.s. And canadian commercial rights through sept 30, 2016 .Vivus inc says preparing to commercialize stendra in u.s. While maintaining discussions to license or sell stendra's u.s. Commercialization rights.  Full Article

Vivus posts qtrly rev $13.8 mln vs $23.0 mln last year
Thursday, 4 Aug 2016 04:15pm EDT 

Vivus Inc : Qtrly loss per share $0.11 .Qtrly revenue $13.8 million versus $23.0 million.  Full Article

Vivus Inc says has files lawsuit -- 8-K
Wednesday, 27 Jul 2016 04:22pm EDT 

Vivus Inc : Says lawsuit was filed in response to an abbreviated new drug application filed by Hetero .Vivus Inc says has filed lawsuit in U.S. District court for district of New Jersey against Hetero USA, Inc. and Hetero Labs Limited.  Full Article

Vivus says to extend return date of Stendra commercial rights
Thursday, 30 Jun 2016 04:15pm EDT 

Vivus Inc : Vivus Inc says to extend return date of Stendra commercial rights .Extension of termination date of license agreement between Auxilium Pharmaceuticals and Vivus for Stendra â U.S. and Canadian commercial rights through August 31.  Full Article

Vivus files lawsuit against Teva for infringement of Qsymia Patents
Wednesday, 15 Apr 2015 07:30pm EDT 

Vivus Inc:Files a lawsuit in the U.S. District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd., collectively referred to as Teva.Lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Teva.VIVUS filed the lawsuit on the basis that Teva's proposed generic products infringe each of these patents held by VIVUS.  Full Article

More From Around the Web

BRIEF-Vivus entered into settlement agreement with Hetero on Jan. 3

* On Jan 3, co entered into a settlement agreement with hetero - sec filing